Amyloid-β Metabolite sensing: Biochemical linking of glycation modification and misfolding

Journal of Alzheimer's Disease

Volumn 30, Issue 1, 2012, Pages 63-73

  Fawver, Janelle N ^a   Schall, Hayley E ^a   Petrofes Chapa, Rachel D ^a   Zhu, Xiongwei ^b   Murray, Ian V J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Advanced glycation endproducts; glycation; glyceraldehyde; glyceraldehyde 3 phosphate; metabolic dysfunction; protein misfolding

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN[1-42]; ARGININE; GLYCERALDEHYDE; GLYCERALDEHYDE 3 PHOSPHATE; MALONALDEHYDE; METHYLGLYOXAL;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN TISSUE; GLYCATION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; LIPID OXIDATION; MALE; MASS SPECTROMETRY; METABOLIC DISORDER; PATHOGENESIS; PRIORITY JOURNAL;

EID: 84861521520     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112114     Document Type: Article

References (54)

1. Miranda HV, Outeiro TF (2010) The sour side of neurodegen-erative disorders: The effects of protein glycation. J Pathol 221, 13-25.
2. Harrington CR, Colaco CALS (1994) Aglycation connection. Nature 370, 247-248.
3. Krautwald M, Münch G (2010) Advanced glycation end products as biomarkers and gerontotoxins-A basis to explore methylglyoxal-lowering agents for Alzheimer's disease? Exp Gerontol 45, 744-751.
4. Murray IVJ, Proza JF, Sohrabji F, Lawler JM (2011) Vascular and metabolic dysfunction in Alzheimer's disease: A review. Exp Biol Med 236, 772-782.
5. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi Si, Takeuchi M (2006) Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Dement 21, 197-208. (Pubitemid 44051058)
6. Lüth HJ, Ogunlade V, Kuhla B, Kientsch-Engel R, Stahl P, Webster J, Arendt T, Munch G (2005) Age-and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex 15, 211-220. (Pubitemid 40111081)
7. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18, 172-176.
8. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91, 5710-5714. (Pubitemid 24174398)
9. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G (1995) Early AGEing and Alzheimer's. Nature 374, 316-316.
10. Kristal BS, Yu BP (1992) An emerging hypothesis: Synergistic induction of aging by free radicals and Maillard reactions. J Gerentol 47, B107-B114.
11. Rahmadi A, Steiner N, Munch G (2011) Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clin Chem Lab Med 49, 385-391.
12. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 32, 763-777.
13. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153, 1149-1155. (Pubitemid 28465838)
14. Munch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P (1998) Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105, 439-461. (Pubitemid 28365028)
15. Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yam-agishi Si, Kikuchi S, Saito T (2004) Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 108, 189-193. (Pubitemid 39199509)
16. Dukic-Stefanovic S, Schinzel R, Riederer P, Munch G (2001) AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2, 19-34. (Pubitemid 32780866)
17. Kimura T, Takamastu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S (1995) Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport 6, 866-868.
18. Richter T, Munch G, Lüth HJ, Arendt T, Kientsch-Engel R, Stahl P, Fengler D, Kuhla B (2005) Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts". Neurobiol Aging 26, 465-474. (Pubitemid 40093930)
19. Kitahara Y, Takeuchi M, Miura K, Mine T, Matsui T, Yamag-ishi S (2008) Glyceraldehyde-derived advanced glycation end products (AGEs). A novel biomarker of postprandial hyper-glycaemia in diabetic rats. Clin Exp Med 8, 175-177.
20. Takeuchi M, Yamagishi Si (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 14, 973-978. (Pubitemid 351753285)
21. Chen K, Kazachkov M, Yu PH (2007) Effect of aldehydes derived from oxidative deamination and oxidative stress on fj-amyloid aggregation; pathological implications to Alzheimer's disease. J Neural Transm 114, 835-839. (Pubitemid 46980494)
22. Kuhla B, Lüth HJ, Haferburg D, Boeck K, Arendt T, Munch G (2005) Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann NY Acad Sci 1043, 211-216. (Pubitemid 41123908)
23. de Arriba SG, Stuchbury G, Yarin J, Burnell J, Loske C, Munch G (2007) Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells-protection by carbonyl scavengers. Neurobiol Aging 28, 1044-1050. (Pubitemid 46635909)
24. Takahashi H, Tran PO, LeRoy E, Harmon JS, Tanaka Y, Robertson RP (2004) d-Glyceraldehyde causes production of intracellular peroxide in pancreatic islets, oxidative stress, and defective beta cell function via non-mitochondrial pathways. J Biol Chem 279, 37316-37323. (Pubitemid 39195439)
25. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91, 4766-4770. (Pubitemid 24177730)
26. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G (2000) Transition metal-mediated glycoxidation accelerates cross-linking of fj-amyloid peptide. Eur J Biochem 267, 4171-4178. (Pubitemid 30436113)
27. Guix FX, Ill-Raga G, Bravo R, Nakaya T, de Fabritiis G, Coma M, Miscione GP, Villa-Freixa J, Suzuki T, Fernandez-Busquets X, Valverde MA, De Strooper B, Muñoz FJ (2009) Amyloid-dependent triosephosphate isomerase nitrotyrosi-nation induces glycation and tau fibrillation. Brain 132, 1335-1345.
28. Castellani RJ, Harris PLR, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith MA (2001) Active glycation in neurofibrillary pathology of Alzheimer disease: Ne-(Carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 31, 175-180. (Pubitemid 32607584)
29. Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ (2003) Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J Alzheimers Dis 5, 467-476. (Pubitemid 38101235)
30. Murray IVJ, Liu L, Komatsu H, Uryu K, Xiao G, Lawson JA, Axelsen PH (2007) Membrane-mediated amyloidogene-sis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem 282, 9335-9345. (Pubitemid 47104603)
31. Giasson BI, Duda JE, Murray IVJ, Chen QP, Souza JM, Hur-tig HI, Ischiropoulos H, Trojanowski JQ, Lee VMY (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
32. Murray IVJ, Medford MA, Guan HP, Rueter SM, Trojanowski JQ, Lee VMY (2003) Synphilin in normal human brains and in synucleinopathies: Studies with new antibodies. Acta Neuropathol 105, 177-184. (Pubitemid 36798804)
33. Kohjima M, Sun Y, Chan L (2010) Increasedfoodintake leads to obesity and insulin resistance in the Tg2576 Alzheimer's disease mouse model. Endocrinology 151, 1532-1540.
34. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17, 500-506. (Pubitemid 39574882)
35. Rodriguez-Rivera J, Denner L, Dineley KT (2011) Rosigli-tazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 216, 255-261.
36. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795. (Pubitemid 44622683)
37. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, Hebert SS, De Strooper B, Haass C, Bennett DA, Vassar R (2008) Phosphorylation of the translation initiation factor eIF2a increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 988-1009.
38. Tyedmers J, Madariaga ML, Lindquist S (2008) Prion switching in response to environmental stress. PLoS Biol 6, e294.
39. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER (2010) Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 140, 421-435.
40. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid beta: The alternate hypothesis. Curr Alzheimers Res 3, 75-80.
41. Krebs B, Wiebelitz A, Balitzki-Korte B, Vassallo N, Paluch S, Mitteregger G, Onodera T, Kretzschmar HA, Herms J (2007) Cellular prion protein modulates the intracellular calcium response to hydrogen peroxide. J Neurochem 100, 358-367. (Pubitemid 46010997)
42. Vassallo N, Herms J (2003) Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J Neurochem 86, 538-544. (Pubitemid 36897434)
43. Hardy J, Cullen K (2006) Amyloid at the blood vessel wall. Nat Med 12, 756-757. (Pubitemid 44050057)
44. Hardy J (2007) Does Afj42 have a function related to blood homeostasis? Neurochem Res 32, 833-835. (Pubitemid 46481311)
45. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
46. Kokjohn TA, Maarouf CL, Roher AE (2011) Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement, doi: 10.1016/j.jalz.2011.05.2429.
47. Bailey JA, Maloney B, Ge YW, Lahiri DK (2011) Functional activity of the novel Alzheimer's amyloid fj-peptide interacting domain (AfjID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488, 13-22.
48. Maloney B, Lahiri DK (2011) The Alzheimer's amyloid fj-peptide (Afj) binds a specific DNA Afj-interacting domain (AfjID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. Gene 488, 1-12.
49. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128. (Pubitemid 121003917)
50. Khan MA, Baseer A (2000) Increased malondialdehyde levels in coronary heart disease. J Pak Med Assoc 8, 261-264.
51. Kang HK, Kim DK, Lee BH, Om AS, Hong JH, Koh HC, Lee CH, Shin IC, Kang JS (2001) Urinary N-acetyl-fj-D-glucosaminidase and malondialdehyde as a markers of renal damage in burned patients. J Korean Med Sci 16, 598-602. (Pubitemid 33741668)
52. MacDonald MJ, Chaplen FWR, Triplett CK, Gong Q, Drought H (2006) Stimulation of insulin release by glyc-eraldehyde may not be similar to glucose. Arch Biochem Biophys 447, 118-126.
53. Lapolla A, Flamini R, Vedova AD, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P (2003) Glyoxal and methylglyoxal levels in diabetic patients: Quantitative determination by a new GC/MS method. Clin Chem Lab Med 41, 1166-1173. (Pubitemid 37265695)
54. Olah J, Orosz F, Puskas LG, Hackler L, Horá́inyi M, Polgar L, Hollan S, Ovadi J (2005) Triosephosphate isomerase deficiency: Consequences of an inherited mutation at mRNA, protein and metabolic levels. Biochem J 392, 675-683. (Pubitemid 43022748)